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Abstract:  Problem  statement:  Brucellosis  is  a  globally  found  infectious  disease  and  there  is  no 
licensed vaccine against human brucellosis. The present study carried-out to evaluate the potency of 
our  modified  extracted  lipopolysaccharide  (LPS)  of  B.  abortus  to  elicit  specific  anti-Brucella 
antibodies  in  animal  model  (Rabbit)  as  a  part  of  a  candidate  vaccine  for  brucellosis. 
Lipopolysaccharide is one of the main virulence factors and the most immunogenic structure of smooth 
strains  of  Brucella.  Approach:  Lipopolysaccharide  of  B.  abortus  S99  (S-LPS)  initially  extracted 
through an optimized method as described previously. After biochemical and pyrogenicity evaluations 
of the extracted S-LPS humoral immune response against the extracted LPS analyzed in animal model 
through serological assays such as Rose Bengal assay, Rapid agglutination (Rapid Wright) test and 
Standard agglutination test (SAT or Wright test) to demonstrate the specific elicited antibodies against 
the injected LPS. In addition, the interaction of LPS and anti-LPS antibodies was demonstrated by 
Agarose Gel Immunodiffusion (AGID) assay. Results: Higher doses of B. abortus S99 LPS caused 
less  or  equal  body  temperature  increase  in  comparison  to  E.  coli  LPS  doses.  Sera  of  immunized 
animals had been reported positive by RBT because of B. abortus LPS immunogenicity which we 
extracted through our optimized method. The highest titer of anti-Brucella antibodies detected two 
weeks after the third immunization (assayed by rapid slide agglutination and standard agglutination 
tests). Anti-Brucella antibodies   of   immunized   animals  reacted more specifically with the LPS of 
B. abortus in comparison with E. coli LPS and precipitation lines between B. abortus LPS and immune 
sera  appeared  after  30  min  while  detected  after  three  hours  for  E.  coli  LPS. 
Conclusions/Recommendations: The properties of B. abortus S99 LPS concluded from the present 
study  results,  suggest  the  possible  use  of  this  component  as  a  carrier  or  a  part  of  a  sub-unit  or 
conjugated vaccine for human brucellosis. 
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INTRODUCTION 
 
  Brucella  abortus  is  a  bacterium  that  can  cause 
abortions  in  cattle  and  a  debilitating  fever  (undulant 
fever)  that  may  persist  intermittently  for  years  in 
humans. This disease is worldwide, with areas of high 
endemicity  such  as  the  Mediterranean,  Middle  East, 
Latin America and Asia
[1,2]. The incidence in humans 
ranges widely between different regions, with values of 
up to 200 cases per 100,000 populations.  
  Human brucellosis  has a  great variety of clinical 
manifestations,  making  it  difficult  to  diagnose 
clinically. Therefore, the diagnosis must be confirmed 
by isolation of Brucella, mostly from blood culture or 
by the detection of an immune response to its antigens 
such  as  lipopolysaccharide  (LPS).  The  diagnosis  of 
brucellosis  based  exclusively  on  Brucella  isolation 
presents  several  drawbacks.  The  slow  growth  of 
Brucella in primocultures may delay diagnosis for more 
than 7 days
[3,4]. Also, blood culture sensitivity is often 
low,  ranging  from  (50-90%)  depending  on  disease 
stage,  Brucella  species,  culture  medium,  quantity  of 
circulating  bacteria  and  the  blood  culture  technique 
employed
[5,6]. Hence, serological tests play a major role Am. J. Infect. Dis., 5 (1): 11-16, 2009 
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in cases when the disease cannot be detected by blood 
culture.  However,  the  interpretation  of  these  tests  is 
often  difficult,  particularly  in  patients  with  chronic 
brucellosis, in reinfections and relapses and in areas of 
endemicity, where a high portion of the population have 
antibodies  against  brucellosis.  Many  serological  tests 
have been used for the diagnosis of human brucellosis. 
The  most  commonly  used  tests  are  the  Serum 
Agglutination  Test  (SAT),  the  Coombs  anti-Brucella 
test,  the  Rose  Bengal  Test  (RBT)  and  complement 
fixation. During the last decade, radioimmunoassay
[7,8] 
and  enzyme  immunoassay
[9-10]  tests  have  also  been 
used.  These  present  technical  difficulties  since  they 
require skilled personnel and high-cost material. Also, 
interpretation  of  enzyme  immunoassay  results  is 
difficult due to the variability of antigens and technical 
procedures employed. Among the techniques used for 
the  diagnosis  of  human  brucellosis,  SAT  and  the 
Coombs test are most often used and their performance 
in disease diagnosis and during disease evolution has 
been studied thoroughly
[11]. LPS is known as the main 
virulence factor of Brucella and LPS deficient strains 
have less virulence and intra-cellular survival potency. 
Agarose Gel-Immuno  Diffusion (AGID) test also has 
been  reported  to  be  a  simple  and  rapid  assay  to 
demonstrate  antibodies  elicited  against  Brucella 
antigens (especially LPS)
[12].  
  The  LPS  of  B.  abortus  has  been  extensively 
evaluated and studied. Different strains of B. abortus 
are classified to rough and smooth based on the LPS 
they  express  (rough  LPS  and  smooth  LPS, 
respectively).Wild  type  Brucellae  mainly  express 
smooth LPS (S-LPS) and it is the main antigenic and 
immunogenic structure on the surface of smooth strains 
of  Brucella.  B.  abortus  S-LPS  (as  same  as  the  most 
gram  negative  bacteria)  consists  of  three  domains: 
Lipid  A,  Core  oligosaccharide  and  O  specific 
polysaccharide  (O-antigen)  but  possesses  a  peculiar 
non-classical  LPS  as  compared  with  LPS  of 
Enterobacteria such as E. coli. The lipid A of B. abortus 
LPS consists of special fatty acids (different from the 
other gram  negative bacteria) and a unique structure. 
This  moiety  of  B.  abortus  LPS  possesses  a  diamino 
glucose backbone and the acyl groups are longer (C18-
19,  C28)  and  are  only  linked  to  the  core  by  amide 
bounds.  Further  the  O-antigen  of  Brucella  LPS  is  a 
homopolymer  of  perosamine  (4,  6-dideoxy-4-
formamido-d-mannopyranosyl). Since LPS is the main 
expressed  antigen  on  the  surface  of  Brucella  the 
serologic  responses  following  Brucella  infection  are 
directed against LPS. Thus in human and animal, the 
serological diagnosis of brucellosis is mainly based on 
the detection of specific anti-LPS antibodies
[13]. 
  In the present study we have initially extracted the 
LPS of B. abortus S99 (S-LPS) through an optimized 
method  as  described  previously.  After  biochemical 
evaluations  of  the  extracted  S-LPS  we  analyzed  the 
humoral immune response against the extracted LPS in 
animal  model  via  serological assays  such as the rose 
bengal  assay,  rapid  agglutination  (rapid  wright)  test, 
Serum Agglutination Test (SAT or wright test) and 2-
ME Wright test to demonstrate specific IgM and IgG 
antibodies elicited against the injected LPS. In addition, 
the  interaction  of  LPS  and  anti-LPS  antibodies 
demonstrated  by  Agarose  Gel  Immunodiffusion 
(AGID) assay. 
 
MATERIALS AND METHODS 
 
Bacteria strain  and   cellular biomass production: 
B. abortus S99 obtained from the collection of standard 
bacteria, Pasteur institute of Iran (Tehran). To achieve 
the  cellular  biomass  of  B.  abortus  S99  fermentation 
process carried out as previously described
[14]. Briefly, 
Microorganism  was  cultured  in  slant  Brucella  agar 
medium (Merck) at 37±1°C for 72 h and then cultured 
in a 5 L flask containing 2 L Brucella broth (Merck) for 
72 h to achieve the seed culture. Seed culture inoculated 
to the 60 liter industrial fermentor (Novapaljas, contact-
flow  B.V,  Netherlands)  with  40  L  working  volume. 
Finally biomass of B. abortus S99 deactivated by (10%) 
phenol (w/w) and harvested  through centrifugation at 
3800 rpm. 
 
LPS Extraction procedure and chemical analysis of 
extracted sample: As it is previously described LPS of 
B. abortus S99 extracted by an optimized method based 
on hot phenol-water extraction and the extracted sample 
was chemically analyzed to define the content of LPS, 
Keto  Deoxy  Octanate  (KDO),  protein  and  nucleic 
acids
[13]. 
 
Rabbit pyrogen test: Five groups of rabbits weighing 
2.5-3 kg were injected with B. abortus S99 LPS at a 
concentration  of  100,  10,  1,   0.1,  or  0.01 mg  mL  in 
3  mL  kg
-1  of  body  weight.  Each  group  consisted  of 
three  rabbits.  The  baseline  rectal  temperature  was 
recorded before injections and after 30 min the rabbits 
were  inoculated  in  the  ear  vein.  Temperatures  were 
recorded  every  h  for  3  h.  As  a  comparative  study, 
pyrogenicity of E. coli LPS assayed by another rabbit 
pyrogen test as same as B. abortus S99 LPS. The test 
indicates the presence of a pyrogen  when one of the 
three rabbits has an increase in body temperature higher 
than  0.6°C  or  when  the  sum  of  the  maximum 
temperature rises in the three individual rabbits exceeds 
1.4°C
[15]. Am. J. Infect. Dis., 5 (1): 11-16, 2009 
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Immunization schedule: 10 mg mL
-1 of B. abortus S99 
LPS injected (intramuscular) to a  group of 3 rabbits. 
Then animal models inoculated with booster injections 
in 14 and 28 days after the first injection. The animals 
were bled on the days 0 (before any immunization and 
as  the  negative  control),  14  (before  the  first  booster 
injection), 28 (before the second booster injection) and 
42  (two  weeks  after  the  second  injection)  and  the 
immune sera were separated, pooled and kept in -20°C. 
 
Detection  of  synthesized  antibodies  against  B. 
abortus S99 LPS: Presence  of  Anti-Brucella abortus 
S99  LPS  in  the  sera  of  immunized  animals 
demonstrated by Rose Bengal test (RBT), SAT (tube 
agglutination  and  rapid  slide  agglutination)  and 
Agarose Gel-Immuno Diffusion (AGID)
[16]. 
  
Rose  bengal  test  (RBT): 30  mL of animal sera and 
30 mL of rose bengal antigen (obtained from bacterial 
vaccines and antigens production department of Pasteur 
Institute of Iran, Tehran) mixed together on a slide and 
gently  shook  for  four  min  at  the  room  temperature. 
Simultaneously  a  similar  process  done  for  standard 
antiserum (Pasteur Institute of Iran, Tehran) and finally 
positive  serum  samples  (containing  anti-Brucella 
antibodies)  detected  through  observation  of 
agglutination.  
 
Rapid  slide  agglutination  test:  Serial  dilution  of 
animal  serum  samples  made  from  1/20-1/640  on  a 
scaled (cellular) flat slide. Each of the diluted samples 
mixed to a drop of standard antigen (Pasteur Institute of 
Iran, Tehran) and gently shook for a min. Also a drop 
of standard antigen was added to one of the squares of 
scaled slide as the negative control. The highest serum 
dilution showing (50%) agglutination was considered as 
the titer of serum. 
 
Standard agglutination test: Serial dilution of animal 
serum   samples   (0.5  mL)  made from 1/20-1/5120 in 
9  different  tubes.  Then  0.5  mL  of  standard  antigen 
(Pasteur Institute of Iran, Tehran) added to each sample. 
Also 0.5 mL of the standard antigen added to 0.5 mL of 
normal saline as the negative control. Samples kept at 
37°C for 24 h and finally analyzed to detect the positive 
samples  and  the  titer  of  sera  in  comparison  to  the 
negative control. The highest serum dilution  showing 
(50%)  agglutination  was  considered  as  the  titer  of 
serum. 
 
Agarose gel-immunodiffusion (AGID) test: The gel 
was  prepared  by  dissolving  (1.8%)  agarose  in  0.1  M 
Barbital  buffer  (pH  8.6).  NaCl  had  been  added  to  a 
concentration of (20%) to the barbital buffer. Prepared 
gel dispensed on plates at 65°C to a depth of 3 mm. 
After  the  gel  had  set,  4-mm  wells  were  cut  and 
removed.  The  pooled  serum  of  Immunized  animals 
added  at  the  center  of  plate  and  extracted  LPS  of 
Brucella  abortus  S99  and also standard LPS of E. coli 
added  at  the  wells  surrounding  the  central  well 
(containing  the  serum  of  immunized  animal). 
Precipitation  could  appear  within  30  min,  but  final 
readings were taken at three h. 
 
RESULTS 
 
Rabbit pyrogen test: As the Fig. 1 shows, higher doses 
of  B.  abortus  S99  LPS  causes  less  or  equal  body 
temperature  increase  in  comparison  to  E.  coli  LPS 
doses.   According  to   this   graph,  10
-1 mg   mL
-1 of 
B.  abortus  S99  LPS  caused  6°C  rise  of  body 
temperature following the injection while 10
-5 mg mL
-1 
of E. coli LPS increased equal body temperature.  
 
RBT:  As  the  Table  1  shows,  sera  of  immunized 
animals have been reported positive by RBT while the 
negative  control  serum  (sample  taken  before 
immunization) did not react with rose bengal antigen 
(agglutination was not observed). 
 
Rapid slide agglutination test: Titer of anti-Brucella 
antibodies  in  the  sera  of  immunized  animals, taken 
2 weeks after the first, second and third immunization 
reported to be 160, 320 and 640, respectively while no 
agglutination has been observed in the negative control 
(Table 2). 
 
 
 
Fig. 1:  Rabbit  pyrogen  test.  Increased  body 
temperatures  (from  the  baseline)  of  animal 
models  injected with B. abortus S99 LPS and 
E. coli  LPS  at  the  doses indicated. Ba-LPS: 
B. abortus LPS, Ec-LPS: E. coli LPS Am. J. Infect. Dis., 5 (1): 11-16, 2009 
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Table 1: Results of RBT 
  0  14 (2 weeks after the  28 (2 weeks after the  48 (2 weeks after the 
Day of sampling  (Negative control)  first immunization)  second immunization)  third immunization) 
RBT  -  +  +  + 
 
Table 2: Results of rapid slide agglutination test 
  0  14 (2 weeks after the  28 (2 weeks after the  42 (2 weeks after the 
Day of sampling  (negative control)  first immunization)  second immunization)  third immunization) 
Rapid slide agglutination test  -  160  320  640 
 
Table 3: Results of tube agglutination test 
    14 (2 weeks after the  28 (2 weeks after the  42 (2 weeks after the 
Day of sampling  0 (negative control)  first immunization)  second immunization)  third immunization) 
Tube agglutination test  -  320  640  1280 
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Fig. 2: The  Increase  of  anti-B.  abortus  antibody  titer 
after  booster  injections  (assayed  by  standard 
agglutination test) 
 
Standard agglutination test: As the Table 3 shows, no 
agglutination  ring  appeared  at  the  bottom  of  the 
negative  control  tube  after  24  h.  The  highest  titer  of 
anti-Brucella antibody has been shown in the sample 
that  was  taken  2  weeks  after  the  third  immunization 
(1280) while the titer of samples taken 2 weeks after the 
first and second immunization reported to be 320 and 
640, respectively (Fig. 2). 
 
AGID  test:  The  precipitation  reaction  between  the 
pooled serum of immunized animals and the extracted 
LPS of B. abortus S99 has been observed after 30 min 
but this reaction did not occur between standard LPS of 
E. coli and the pooled serum of immunized animals in 
the same period of time. Finally after three h a thin line 
between E. coli LPS and the pooled serum appeared, 
indicating    some    structural  similarities  between  the 
LPS of B. abortus S99 and E. coli LPS, while it was 
thick and sharp between B. abortus S99 LPS and the 
pooled      serum    because  of  the  specificity  of 
synthesized  antibodies  against  the  LPS  of  B.  abortus 
S99 (Fig. 3). 
 
 
Fig. 3: AGID  test  confirms  the  specificity  of 
synthesized antibodies in the animal model for 
the extracted LPS of B. abortus S99. Also after 
3 h a thin line observed between pooled serum 
of immunized animals and E. coli LPS. 1: LPS 
of E. coli, 2, 3, 4: LPS of B. abortus S99 
 
DISCUSSION 
 
  Lipopolysaccharide  (LPS)  is  the  main  expressed 
antigenic structure at the surface of smooth strains of 
Brucella abortus. In the present study we analyzed the 
efficacy of the extracted LPS of Brucella abortus S99 
(extracted through our optimized method)
 [14] to induce 
the  anti-Brucella  antibodies  in  the  animal  model 
following  the  intramuscular  injection  of  this  antigen 
and two booster injections. Sera of all the immunized 
animals  have  been  detected  as  positive  samples, 
indicating the potency of this extracted LPS of Brucella 
abortus  S99.  The  highest  antibody  titer  has  been 
detected  2  weeks  after  the  second  injection 
(demonstrated by tube and slide agglutination methods 
and  has  been  reported  to  be  640  and  1280, 
respectively).  Booster  injections  have  efficiently 
increased  the  titer  of  elicited  antibodies  against 
Brucella  and  there  was  a  considerable  rise  in  the 
assayed titer of analyzed serum samples (Fig. 2). The Am. J. Infect. Dis., 5 (1): 11-16, 2009 
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results of Rose Bengal Test (RBT) has been in parallel 
with Serum agglutination assay results but as RBT is 
not  a  quantitative  method  it  may  be  applied  only  to 
detect  positive  and  negative  samples  and  should  be 
followed by agglutination assays to detect the titer of 
samples. 
  Currently Serum Agglutination Test (SAT) is the 
most commonly used and accepted assay to detect the 
titer  of  anti-Brucella  antibodies
  [17].  Other  serology 
methods  such  as  rose  bengal  and  agarose  gel 
immunodiffusion  tests  may  be  applied  to  distinguish 
positive and negative serum samples (but not the titer). 
Since the tube agglutination assay is a time-consuming 
assay and the process of this method takes at least 24 h, 
slide  (rapid)  agglutination  assay  may  be  applied  to 
detect the titer of anti-Brucella antibodies in the serum 
of patients and also in the animal models. In the present 
study, tube agglutination assay results were in parallel 
with  the  slide  (rapid)  agglutination  results  but  there 
were  one  titer  difference  between  these  two  methods 
results. 
  In the present study the specificity of synthesized 
antibodies   in   the  sera  of  immunized  animals   for 
B.  abortus  S99  LPS  assayed  by  agarose  gel-
Immunodiffusion method in comparison to E. coli LPS. 
As  it  is  mentioned  in  the  Results,  pooled  serum  of 
immunize  animals  react  rapidly  with  B.  abortus  S99 
LPS  during  the  first  30  min  of  the  test  and  a  sharp 
precipitation  line  observed  between  the  wells 
containing B. abortus S99 LPS and the well containing 
pooled  serum  of  immunized  animals,  while  no 
precipitation  occurred between the pooled serum and 
E.  coli LPS during the same time. Interestingly a thin 
line of precipitation between pooled serum and E. coli 
LPS observed after 3 h. Since the animals have been 
injected with B. abortus S99 LPS (not E. coli LPS) it 
could be concluded that this relative reaction may be a 
sign of some structural similarities between B. abortus 
S99 LPS and E. coli LPS. It is also previously reported 
that the  main structural differences between Brucella 
and E. coli LPS is in the O chain of these two kind of 
LPS and other parts of this structure is almost the same 
in  Brucella  and  E.  coli.  These  structural  similarities 
may  lead  to  a  poor  cross-reaction  between  the 
antibodies  elicited   against   B. abortus S99 LPS with 
E.  coli  LPS  and  it  seems  to  be  the  main  reason  of 
reactivity of pooled serum of immunized animals with 
E. coli LPS in this study. 
   AGID test has been previously applied to detect 
positive serum samples of infected dogs and cattle with 
rough  strains  of  B.  canis  and  B.  melitensis  16  M, 
respectively and reported to be a sensitive, rapid and 
reliable method
[18]. In the present study, we showed that 
this  method  would  be  efficiently  used  for  smooth 
strains of Brucella such as B. abortus S99. 
  Rabbit pyrogen test is one of the Invivo assays to 
evaluate the pyrogenicity of biologic compounds such 
as LPS and other bacterial antigens. In the present study 
we evaluated the pyrogenicity of our extracted LPS of 
B. abortus S99 in comparison with E. coli LPS. As the 
Fig.  2  shows  injection  of  low  doses  of  E.  coli  LPS 
cause  higher  increase  of  body  temperature  in 
comparison to B.   abortus LPS  which  confirms  that 
E. coli LPS is more toxic and pyrogenic than B. abortus 
S99  LPS.  As  the  graph  shows,  10
-1   mg    mL
-1 of 
B. abortus S99 LPS and 10
-5 mg mL
-1 of E. coli LPS 
have equally increased the body temperature following 
the injection. These data confirm previous study and the 
fact  that  Brucella  abortus  LPS  is  10,000  fold  less 
pyrogenic than E. coli LPS
  [15]. Nowadays decreasing 
the  pyrogenicity  of  immunogenic  compounds  with 
microbial origins is one of the strategies to make them 
applicable  for  Invivo  trials  and  immunization. 
Unfortunately,  the  process  of  decreasing  the 
pyrogenicity usually leads to less immunogenicity, too. 
According to this fact, the application of B. abortus S99 
LPS  for  Invivo  and  immunization  aims  would  be 
advantageous because of its low pyrogenicity and high 
potency to induce antibodies against Brucella.  
 
CONCLUSION 
 
  This modified extracted LPS of B. abortus S99 has 
efficiently promoted the synthesis of high levels of anti-
Brucella  antibodies.  Furthermore,  elicited  antibodies 
reacted specifically with the extracted LPS which has 
been  intramuscularly  administrated  to  animal  models 
(demonstrated by AGID). 
  Potency  of  LPS  to  induce  high  titers  of  specific 
antibodies  against  Brucella  in  parallel  with  low 
pyrogenicity of this cellwall structure (defined by rabbi 
pyrogen test) suggests the possible application of this 
component as a part of a sub-unit or conjugated vaccine 
for human brucellosis. 
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